RecruitingNCT06403202

Prognostic Performance of a Chemogram in Patients With Bladder Cancer.

Prognostic Performance of a Chemogram in Patients With Intermediate-grade Superficial Bladder Cancer and Invasive Bladder Cancer: Proof of Concept.


Sponsor

Lille Catholic University

Enrollment

60 participants

Start Date

Aug 23, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of the study is to evaluate chemogram in patients with intermediate-grade superficial bladder cancer and patients with infiltrating bladder cancer, who are likely to be treated according to the standard procedure. This project is based on the premise that treatments - notably chemotherapy - are standard, but that each cancer is unique. It is therefore necessary to personalize the treatment for each patient, while at the same time proposing an approach that is economically bearable for the healthcare system. For both types of bladder tumor, chemotherapy is used either as an alternative to immunotherapy, or as an adjuvant to surgery. Its use is therefore based on its effectiveness in reducing post-treatment recurrence.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Major patient
  • Patient with suspected bladder cancer likely to be treated with chemotherapy
  • Patient affiliated to a social security scheme

Exclusion Criteria4

  • Insufficient tumor volume
  • Patient under guardianship
  • Pregnant or breast-feeding women
  • Patient opposed to participation in the study

Locations(1)

Hôpital St Philibert

Lomme, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06403202


Related Trials